Bevacizumab in the treatment of HER2-negative breast cancer.
Angiogenesis has a clear and definite role in the breast cancer progression process, making antivascular endothelial growth factor (VEGF) therapies an attractive option for the treatment of metastatic breast cancer (MBC). Bevacizumab is a potent humanized monoclonal antibody to VEGF, which has shown regression of breast cancer in preclinical and clinical setting, either alone or in combination with cytotoxic treatment. Additionally, bevacizumab potentially increases the effectiveness of other anticancer therapies through the normalization of tumor vasculature, reduction of intratumoral pressure and improved tumor oxygenation. Phase 1/2 trials showed significant antitumor effects of bevacizumab in MBC, in particular in tumors not expressing HER2 receptor. A first phase 3 trial in pre-treated MBC patients showed better response rates but no survival benefit from the addition of bevacizumab to capecitabine. However, in two phase 2 trial in first-line setting in patients with MBC, bevacizumab improved progression-free survival in combination with weekly paclitaxel in comparison to paclitaxel alone or in combination with 3-weekly docetaxel in comparison with docetaxel alone, respectively. Bevacizumab in combination with taxanes seems to be a highly effective first-line treatment for MBC patients. Future research will investigate bevacizumab in the neoadjuvant or adjuvant setting, where even more potential may exist for these patients.
Lorusso
Vito
V
Oncologic Institute, Vito Fazzi Hospital, Lecce, Italy.
Anticancer Res. 2007 Jul-Aug;27(4B):2279-87
17695515
J Clin Oncol. 2006 Feb 10;24(5):769-77
16391297
Onkologie. 2007 Dec;30(12):606-8
18063872
Clin Adv Hematol Oncol. 2006 Mar;4(3 Suppl 7):suppl 1, 4-9; discussion suppl 10; quiz 2 p following suppl 10
16736568
Ann Oncol. 2012 Feb;23(2):331-7
21821545
N Engl J Med. 2007 Dec 27;357(26):2666-76
18160686
Expert Opin Investig Drugs. 2002 Dec;11(12):1715-36
12457433
Endocr Rev. 1997 Feb;18(1):4-25
9034784
Invest New Drugs. 1997;15(1):39-48
9195288
Semin Oncol. 2003 Oct;30(5 Suppl 16):117-24
14613032
J Clin Oncol. 2005 Oct 1;23(28):7135-42
16192597
J Clin Oncol. 2008 Oct 1;26(28):4672-8
18824714
Cancer Res. 1997 Mar 1;57(5):963-9
9041202
Lancet. 1998 Sep 19;352(9132):930-42
9752815
Clin Cancer Res. 2004 Jun 1;10(11):3577-85
15173063
J Clin Oncol. 2005 Feb 20;23(6):1295-311
15718328
Science. 2005 Jan 7;307(5706):58-62
15637262
Cancer. 2005 Oct 15;104(8):1742-50
16149088
Br J Cancer. 1994 Feb;69(2):212-6
8297716
J Clin Oncol. 2001 Feb 1;19(3):843-50
11157038
Ann Oncol. 2002 Jan;13(1):73-80
11863115
Cancer Res. 2001 Apr 15;61(8):3369-72
11309294
J Clin Oncol. 2008 Oct 20;26(30):4899-905
18794539
Cancer Res. 2002 Dec 1;62(23):6938-43
12460910
Int J Oncol. 2005 Mar;26(3):623-8
15703816
Ann Oncol. 2005 Jul;16(7):999-1004
15939715
Nat Rev Cancer. 2004 Jun;4(6):423-36
15170445
J Clin Oncol. 2001 Feb 1;19(3):851-6
11157039
J Clin Oncol. 2005 Feb 1;23(4):792-9
15681523
Clin Breast Cancer. 2008 Aug;8(4):370-3
18757267
Anticancer Res. 1999 Sep-Oct;19(5B):4203-14
10628376